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Abstract
Background Aspirin is associated with gastrointestinal side
effects such as gastric ulcers, gastric bleeding and dyspepsia.
High-dose effervescent calcium carbasalate (ECC), a buffered
formulation of aspirin, is associated with reduced gastric
toxicity compared with plain aspirin in healthy volunteers,
but at lower cardiovascular doses no beneficial effects were
observed.
Aim To compare the prevalence of self-reported gastrointesti-
nal symptoms between low-dose plain aspirin and ECC.
Methods A total of 51,869 questionnaires were sent to a
representative sample of the Dutch adult general population
in December 2008. Questions about demographics, gastroin-
testinal symptoms in general and specific symptoms, comor-
bidity, and medication use including bioequivalent doses of
ECC (100 mg) and plain aspirin (80 mg) were stated. We
investigated the prevalence of self-reported gastrointestinal
symptoms on ECC compared with plain aspirin using univar-
iate and multivariate logistic regression analyses.
Results A total of 16,715 questionnaires (32 %) were returned
and eligible for analysis. Of these, 911 (5 %) respondents
reported the use of plain aspirin, 633 (4 %) ECC and 15,171
reported using neither form of aspirin (91 %). The prevalence
of self-reported gastrointestinal symptoms in general was
higher in respondents using ECC (27.5 %) compared with
plain aspirin (26.3 %), but did not differ significantly with
either univariate (OR 1.06, 95%CI 0.84–1.33), or multivariate
analysis (aOR 1.08, 95 %CI 0.83–1.41). Also, none of the
specific types of symptoms differed between the two aspirin
formulations.
Conclusions In this large cohort representative of the general
Dutch population, low-dose ECC is not associated with a
reduction in self-reported gastrointestinal symptoms com-
pared with plain aspirin.
Keywords Low-dose aspirin . Effervescent calcium
carbasalate . Gastrointestinal symptoms . Survey .
Community based population
Introduction
Optimal antithrombotic therapy has proven to be essential in
secondary prevention in cardiovascular disease. In this, aspirin
has a pivotal role and is associated with a relative reduction of
approximately 25 % in recurrent cardiovascular events [1].
However, gastric toxicity is a well-known side effect of aspirin
presenting as gastric or duodenal ulcers, bleeding and
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dyspepsia [1–7]. Of these, dyspepsia is most often reported (in
20–40 % of chronic aspirin users) [4, 7, 8] and is associated
with reduced aspirin compliance [9, 10], increased healthcare
costs [11] and reduced health-related quality of life [12].
To reduce gastrointestinal damage, different formulations
of aspirin have been developed. These formulations either
delay the release of aspirin beyond the stomach (enteric-
coated aspirin), facilitate the transit of aspirin across the gas-
tric mucous layer (PL2200), or increase solubility of aspirin
supposedly resulting in lower irritating concentrations on the
gastric mucosa (effervescent calcium carbasalate (ECC)). The
gastric toxicity of different formulations was mainly studied in
high dosages and showed clear benefit over plain aspirin with
respect to gastric ulcer formation when studied in healthy
volunteers [13–18]. However, when investigating its clinical
effect in patients on (low-dose) chronic antiplatelet therapy, no
clear beneficial effect on gastrointestinal side effects was
noticeable [19–22].
In the Netherlands, a total of 1,290,000 patients use low-
dose aspirin of which 41 % are prescribed ECC [23]. No data
have been published comparing the effects of ECC and plain
aspirin on gastrointestinal symptoms. In this population-based
cohort of respondents using low-dose aspirin we studied and
compared the prevalence of gastrointestinal symptoms be-
tween those using ECC and plain aspirin. We also studied
whether respondents using different formulations may report
different types of gastrointestinal symptoms.
Methods
Study population
We sent 51,869 questionnaires by surface mail to a represen-
tative sample of the Dutch population in December 2008.
Invited subjects were aged 18 years and above, and randomly
selected frommunicipal databases of five different municipal-
ities selected on their geographical location in the
Netherlands, in order to gather a representative sample of the
Dutch population. We included returned questionnaires until
31 March 2009. We excluded returned questionnaires with
missing elements that were part of the primary outcome
measure. We also excluded returned questionnaires in which
all baseline characteristics were missing or when the medica-
tion was unreadable or if the used aspirin formulation was not
reported. The complete cohort has been described previously
[24]. The current sample size consisted of those respondents
reporting the use of either low-dose plain aspirin or ECC.
TheMedical Ethical Committee of the Radboud University
Nijmegen assessed the research proposal of this study and
concluded that it could be waived for ethical review, as ques-
tionnaires were returned and stored anonymously, and
(non-)responders would not be contacted again. For this rea-
son, we did not obtain written informed consent.
Questionnaire
The questionnaire has been used before and was specifically
designed for collection of demographic information, gastroin-
testinal symptoms, and medication use [25, 26]. Participants
were asked whether they suffer from gastrointestinal symp-
toms in general and about the presence of 26 gastrointestinal
symptoms such as nausea, early satiety and bloating. Severity
of gastrointestinal symptoms was assessed on a seven-point
Likert scale (0 = absent, 1 = almost absent, 2 = mild, 3 =
moderate, 4 = moderately severe, 5 = severe, 6 = very severe)
over the preceding 4 weeks [27]. A symptom was considered
to be present if the participants scored ≥2 on the Likert scale.
Outcomes
Our primary outcome was the presence of gastrointestinal
symptoms, which was assessed with the question: ‘Do you
experience gastrointestinal complaints?’ and had to be an-
swered with either ‘yes’ or ‘no’. Secondary outcomes were
duration of the primary endpoint and the individual gastroin-
testinal symptoms among responders who reported the pres-
ence of gastrointestinal complaints. The primary and second-
ary outcomes were compared between respondents reporting
the use of low-dose plain aspirin (80mg) and those using ECC
(100 mg).
Statistical analysis
Statistical analyses were performed with SPSS statistical soft-
ware, version 16.0 (SPSS, Inc., Chicago, Illinois, USA).
Frequency tables were provided describing respondents’ base-
line characteristics. Pearson’s chi squared test was used to
compare categorical variables. Continuous variables were
compared with the Student T-test or the Mann–Whitney U
method whenever appropriate. Univariate and multivariate
associations for gastrointestinal endpoints in respondents
using plain aspirin or ECC were analysed using logistic re-
gression. Two-sided p-values of <0.05 were considered statis-
tically significant. Covariates were included in the multivari-
ate analysis if they significantly differed between respondents
using ECC versus plain aspirin. In addition, those covariates
associated with gastrointestinal symptoms at a level of p<0.1
in univariate analysis were included in multivariate analysis.
Using forward selection, a covariate was allowed into the
multivariate model if it influenced the model with a likelihood
ratio significance level of p<0.05, and was removed again if
its significance level exceeded p=0.1 during any of the fol-
lowing steps. The type of formulation used (ECC versus plain
aspirin) was forced into the model.
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With respect to the duration of symptoms and the analyses
of the individual symptoms, only participants reporting the
presence of the primary outcome were selected. The duration
of symptoms was compared using the Mann–Whitney U
method. The individual symptoms were divided into upper
and lower gastrointestinal symptoms and figures were provid-
ed describing their frequencies. The sum of the individual
symptoms present was categorised according to the number
of symptoms present and frequencies were provided.
Results
A total of 18,317 (35 %) questionnaires were returned, of
which 742 unopened for various reasons (Fig. 1). After ap-
plying our predetermined exclusion criteria a total of 16,715
questionnaires were included in our analyses. In total, 911
persons (5.4 %) reported plain aspirin use, 633 ECC (3.8 %)
and 15,171 reported not using any form of aspirin (90.8 %).
Nearly all baseline characteristics differed between partici-
pants with and without aspirin (Supplementary Table 1).
When comparing plain aspirin and ECC, participants using
ECC were older, reported more comorbidity and were using
more concomitant medication (Table 1).
The self-reported prevalence of gastrointestinal symptoms
of no aspirin, plain aspirin, and ECCwere 25.6%, 26.3%, and
27.5 %, respectively. We observed no difference between
plain aspirin and ECC for self-reported gastrointestinal symp-
toms (ECC: OR 1.06, 95 % CI 0.84–1.33). Also after adjust-
ment with multivariate regression for multiple possible con-
founders there was no significant difference between plain
aspirin and ECC for the presence of gastrointestinal symptoms
(ECC: aOR 1.08, 95 % CI 0.83–1.41, Table 2). Among those
reporting gastrointestinal symptoms, respondents using ECC
had a significantly longer history of symptoms (10 years, IQR
4–20) compared with participants using plain aspirin (7 years,
IQR 3–16, p=0.04).
In respondents reporting the presence of gastrointestinal
symptoms and using either plain aspirin or ECC the presence
of no more than one individual upper gastrointestinal symp-
tom was reported by 26.9 % while five or more symptoms
Fig. 1 Flow chart. *Some respondents fulfilled more than 1 exclusion
criterion








Mean age (±SD) (years) 59.7 (15.2) 64.7 (11.3) <0.01
Male (%) 494 (56) 377 (61) 0.09
Smoking (%) 160 (18) 116 (19) 0.74
BMI (±SD) (kg/m2) 26.3 (4.6) 27.0 (4.9) <0.01
Comorbidity (%)
Diabetes mellitus 108 (12) 106 (17) <0.01
Rheumatoid arthritis 53 (6) 54 (9) 0.04
Asthma/COPD 62 (7) 69 (11) <0.01
Coeliac disease 16 (2) 9 (1) 0.61
IBD 27 (3) 18 (3) 0.89
Medication use (%)
PPI 191 (21) 188 (30) <0.01
H2RA 24 (3) 14 (2) 0.60
Antacids 79 (9) 50 (8) 0.59
Paracetamol 474 (52) 276 (44) <0.01
NSAIDs 274 (30) 186 (29) 0.77
Clopidogrel 17 (2) 36 (6) <0.01
Dipyridamole 43 (5) 69 (11) <0.01
Beta blockers 351 (39) 301 (48) <0.01
ACE inhibitors 175 (19) 189 (30) <0.01
Angiotensin-receptor antagonist 103 (11) 83 (13) 0.28
Calcium antagonist 128 (14) 105 (17) 0.17
Diuretics 185 (20) 155 (25) 0.051
Statins 396 (44) 373 (59) <0.01
Systemic corticosteroids 15 (2) 11 (2) 0.89
Oral glucose lowering agents 85 (9) 70 (11) 0.27
Antidepressants 47 (5) 40 (6) 0.33
History (%)
Peptic ulcer disease 69 (8) 76 (12) <0.01
Peptic ulcer bleeding 26 (3) 15 (2) 0.56
SD standard deviation, BMI body mass index, kg/m2 = kilogram per
square meter, COPD chronic obstructive pulmonary disease, IBD inflam-
matory bowel disease, PPI proton pump inhibitor, H2RA H2-receptor
antagonist, NSAID non-steroid anti-inflammatory disease, ACE angioten-
sin converting enzyme
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were reported present by 32.3 %. The most frequently report-
ed upper gastrointestinal symptoms were bloating (61 %),
belching (47 %) and regurgitation (42 %) (Fig. 2a). With
respect to lower gastrointestinal symptoms, 23.0 % reported
no more than one symptom, while 39.0 % experienced the
presence of 5 or more symptoms. Flatulence (70 %) and
borborygmi (56 %) were the most frequently reported lower
gastrointestinal symptoms (Fig. 2b). No significant differ-
ences between plain aspirin and ECC were present for any
of the upper or lower gastrointestinal symptoms.
Discussion
We aimed to compare the prevalence of self-reported gastro-
intestinal symptoms between respondents using plain aspirin
and those who were prescribed ECC. We observed that in
respondents using any form of low-dose aspirin the preva-
lence of gastrointestinal symptoms was 27%. The use of ECC
is not associated with less gastrointestinal symptoms com-
pared with plain aspirin. The most reported upper gastrointes-
tinal symptoms were bloating, belching, and regurgitation,
whereas flatulence and borborygmi were reported most for
lower gastrointestinal symptoms. No differences in the type of
symptoms between users of ECC and plain aspirin were
observed.
The prevalence of gastrointestinal symptoms in our study
cohort is in line with previously reported data of aspirin users
[4, 7, 8]. Interestingly, the prevalence of gastrointestinal
symptoms in our non-aspirin using population is comparable
with those who use aspirin. The selection of our study popu-
lation could have contributed to this finding. Low-dose aspirin
is generally a long-term treatment, i.e. for the remainder of the
patients’ life span. For our study we selected all low-dose
aspirin users from a large cohort of randomly selected partic-
ipants returning the questionnaire. As a result of this study
design the odds that aspirin treatment was recently initiated for
our participants are minimal. Those patients who suffered
from gastrointestinal symptoms during (the initiation of) as-
pirin treatment were likely to receive co-treatment with a
proton pump inhibitor, H2-receptor antagonist or antacid or
were even switched to other antiplatelet agents. Consequently,
our cohort may consist of a selected population of respondents
in whom aspirin is relatively well tolerated. This hypothesis is
supported by the more frequent use of gastroprotective agents
in low-dose aspirin users compared with our non-aspirin using
population (e.g. proton pump inhibitor use: 25 % vs 9 %).
Irrespectively, our data indicate that ECC is of no beneficial
value for gastrointestinal symptoms among our population of
long-term aspirin users.
So far, only two studies have been conducted to investigate
endoscopically proven gastric mucosal damage in users of
ECC and plain aspirin. In a randomised cross-over trial,
Table 2 Multivariate logistic regression model for reporting gastrointes-
tinal symptoms with effervescent calcium carbasalate entered into the
model
aOR 95 % CI P-value
Age (per year increase) 0.98 0.97–0.99 <0.01
Male gender 0.71 0.55–0.92 0.01
Comorbidity
Asthma/COPD 1.54 1.01–2.36 0.046
IBD 2.01 1.00–4.04 0.050
Medication use
PPI 3.96 2.96–5.30 <0.01
H2RA 4.39 2.01–9.57 <0.01
Antacids 2.90 1.90–4.44 <0.01
Paracetamol 1.42 1.09–1.86 <0.01
Effervescent calcium carbasalate 1.08 0.83–1.41 0.57
History
Peptic ulcer disease 2.39 1.60–3.58 <0.01
aOR adjusted odds ratio, CI confidence interval, COPD chronic obstruc-
tive pulmonary disease, IBD inflammatory bowel disease, PPI proton
pump inhibitor, H2RA H2-receptor antagonist
Fig. 2 Type and prevalence of specific upper (a) and lower (b) gastro-
intestinal symptoms in respondents experiencing gastrointestinal symp-
toms categorised by aspirin formulation
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ECC significantly reduced endoscopically observed gastric
erosions and ulcers compared with the bioequivalent dose of
plain aspirin [13]. However, this study assessed healthy vol-
unteers, investigated very high doses of aspirin (650 mg three
times a day) and only studied the short-term effects. More
recently, the effects of low-dose ECC and plain aspirin were
compared in patients using long-term aspirin for cardiovascu-
lar prevention [19]. In this large retrospective cohort study, the
authors concluded that the incidence rates of endoscopically
proven peptic ulcers were not significantly different between
the two groups.
This is the first study comparing the effects of ECC with
plain aspirin for gastrointestinal symptoms. Moreover, in or-
der to obtain a representative sample, persons were randomly
selected through databases of local authorities without strin-
gent inclusion and exclusion criteria. We do acknowledge
some limitations in our study. First, due to our study design,
response bias could be a potential limitation. Due to conceal-
ment we were unable to contact non-responders and compare
their characteristics with responders. To minimise the effect of
response bias all participants were invited with a personalised
invitational letter and were asked explicitly to participate
irrespective of experiencing gastrointestinal symptoms.
Seventy-five percent of all respondents indeed did not report
the presence of gastrointestinal symptoms. Secondly, we did
not study the duration of low-dose aspirin use or the effect of
gastrointestinal symptoms on aspirin compliance. Finally, we
observed important differences in baseline characteristics be-
tween the two aspirin formulations, all to the detriment of
those participants using ECC. This could be an indication that
physicians are more likely to prescribe plain aspirin to the
relatively healthy subjects and preferentially prescribe ECC to
the older and more fragile patients. In order to adjust for this
possible bias we performed multivariate analysis.
Nonetheless, this observation suggesting confounding by in-
dication should be noted and calls for a study with random
allocation of aspirin formulation.
We observed that low-dose ECC is not associated with a
reduction in gastrointestinal symptoms compared with plain
aspirin. This absence of a beneficial effect of ECC over plain
aspirin is in analogy to a previous study indicating that low-
dose ECC is not associated with a reduction in the prevalence
of gastric ulcer complications. Notably, the costs of ECC are
significantly higher compared with plain aspirin (€1.55 vs.
€0.79/month in the Netherlands) [28]. With 530,000 ECC
users in the Netherlands, these additive costs comprise nearly
5 million euro annually. In view of the lack of a beneficial
clinical effect and the higher costs of ECC, we feel that plain
aspirin is the first drug of choice. If gastrointestinal symptoms
occur, we advise to prescribe a relatively cheap proton pump
inhibitor with proven beneficial effects [29–31]. Only if this
does not reduce the symptoms, might one consider ECC as an
alternative to plain aspirin.
In conclusion, the prevalence of gastrointestinal symptoms
among aspirin users in the Dutch community is 27 % with no
difference between effervescent calcium carbasalate and plain
aspirin in overall prevalence and type of symptoms reported.
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